HEADER TRANSFERASE 27-APR-07 2UZE TITLE CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE TITLE 2 INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 2; COMPND 3 CHAIN: A, C; COMPND 4 SYNONYM: P33 PROTEIN KINASE, CYCLIN DEPENDENT KINASE 2; COMPND 5 EC: 2.7.11.22, 2.7.1.37; COMPND 6 ENGINEERED: YES; COMPND 7 OTHER_DETAILS: THR160 PHOSPHORYLATED; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: CYCLIN A2; COMPND 10 CHAIN: B, D; COMPND 11 FRAGMENT: RESIDUES 175-432; COMPND 12 SYNONYM: CYCLIN-A; COMPND 13 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 8 EXPRESSION_SYSTEM_VECTOR: PGEX; SOURCE 9 MOL_ID: 2; SOURCE 10 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 11 ORGANISM_COMMON: HUMAN; SOURCE 12 ORGANISM_TAXID: 9606; SOURCE 13 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 14 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 15 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 16 EXPRESSION_SYSTEM_VECTOR: PET41A KEYWDS TRANSFERASE, ATP-BINDING, PHOSPHORYLATION, CDK2, KINASE, CYCLIN, KEYWDS 2 MITOSIS, CELL CYCLE, CELL DIVISION, NUCLEOTIDE-BINDING, KEYWDS 3 SERINE/THREONINE-PROTEIN KINASE, THIAZOLIDINONE LIGAND EXPDTA X-RAY DIFFRACTION AUTHOR C.M.RICHARDSON,P.DOKURNO,J.B.MURRAY,A.E.SURGENOR REVDAT 5 03-APR-19 2UZE 1 REMARK REVDAT 4 06-MAR-19 2UZE 1 REMARK LINK REVDAT 3 24-FEB-09 2UZE 1 VERSN REVDAT 2 03-JUL-07 2UZE 1 JRNL REVDAT 1 26-JUN-07 2UZE 0 JRNL AUTH C.M.RICHARDSON,C.L.NUNNS,D.S.WILLIAMSON,M.J.PARRATT, JRNL AUTH 2 P.DOKURNO,R.HOWES,J.BORGOGNONI,M.J.DRYSDALE,H.FINCH, JRNL AUTH 3 R.E.HUBBARD,P.S.JACKSON,P.KIERSTAN,G.LENTZEN,J.D.MOORE, JRNL AUTH 4 J.B.MURRAY,H.SIMMONITE,A.E.SURGENOR,C.J.TORRANCE JRNL TITL DISCOVERY OF A POTENT CDK2 INHIBITOR WITH A NOVEL BINDING JRNL TITL 2 MODE, USING VIRTUAL SCREENING AND INITIAL, STRUCTURE-GUIDED JRNL TITL 3 LEAD SCOPING. JRNL REF BIOORG.MED.CHEM.LETT. V. 17 3880 2007 JRNL REFN ISSN 0960-894X JRNL PMID 17570665 JRNL DOI 10.1016/J.BMCL.2007.04.110 REMARK 2 REMARK 2 RESOLUTION. 2.40 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0019 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.40 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 20.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 89.5 REMARK 3 NUMBER OF REFLECTIONS : 60675 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.198 REMARK 3 R VALUE (WORKING SET) : 0.196 REMARK 3 FREE R VALUE : 0.243 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 3234 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.40 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.46 REMARK 3 REFLECTION IN BIN (WORKING SET) : 3676 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2610 REMARK 3 BIN FREE R VALUE SET COUNT : 192 REMARK 3 BIN FREE R VALUE : 0.3250 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 8916 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 44 REMARK 3 SOLVENT ATOMS : 296 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 28.96 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.33000 REMARK 3 B22 (A**2) : -1.44000 REMARK 3 B33 (A**2) : 0.81000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : -0.23000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.311 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.241 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.158 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 6.659 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.939 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.902 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 9188 ; 0.017 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 12486 ; 1.733 ; 1.974 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 1104 ; 6.625 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 391 ;42.857 ;23.964 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 1606 ;18.379 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 43 ;20.723 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 1408 ; 0.123 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 6857 ; 0.006 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 4135 ; 0.218 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 6236 ; 0.306 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 408 ; 0.176 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 51 ; 0.224 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 3 ; 0.231 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 5707 ; 0.965 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 9029 ; 1.697 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 3958 ; 2.449 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 3457 ; 3.777 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : 1 REMARK 3 REMARK 3 NCS GROUP NUMBER : 1 REMARK 3 CHAIN NAMES : B D REMARK 3 NUMBER OF COMPONENTS NCS GROUP : 1 REMARK 3 COMPONENT C SSSEQI TO C SSSEQI CODE REMARK 3 1 B 1 B 999 4 REMARK 3 1 D 1 D 999 4 REMARK 3 GROUP CHAIN COUNT RMS WEIGHT REMARK 3 MEDIUM POSITIONAL 1 B (A): 2084 ; 0.21 ; 0.50 REMARK 3 MEDIUM THERMAL 1 B (A**2): 2084 ; 0.64 ; 2.00 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. REMARK 4 REMARK 4 2UZE COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 27-APR-07. REMARK 100 THE DEPOSITION ID IS D_1290032387. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 21-JUL-03 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 7.00 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-4 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.933 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 70622 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.300 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 87.5 REMARK 200 DATA REDUNDANCY : 2.400 REMARK 200 R MERGE (I) : 0.09000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 8.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: OTHER REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 61.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.10 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: VAPOUR DIFFUSION AT 4 DEG C, 0.1 M REMARK 280 HEPES PH 7.0, 1M LITHIUM SULPHATE, PH 7.00, VAPOR DIFFUSION, REMARK 280 TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 106.31300 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 36.71800 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 106.31300 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 36.71800 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ARG A 297 REMARK 465 LEU A 298 REMARK 465 LEU C 298 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 THR A 39 OG1 CG2 REMARK 470 GLU A 40 CG CD OE1 OE2 REMARK 470 ARG A 199 CG CD NE CZ NH1 NH2 REMARK 470 ASP C 38 CG OD1 OD2 REMARK 470 THR C 39 OG1 CG2 REMARK 470 ARG C 297 CA C O CB CG CD NE REMARK 470 ARG C 297 CZ NH1 NH2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 CG2 VAL C 64 O HOH C 2016 2.09 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 CYS A 177 CB CYS A 177 SG -0.156 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 LEU A 78 CA - CB - CG ANGL. DEV. = 14.0 DEGREES REMARK 500 ARG A 150 NE - CZ - NH1 ANGL. DEV. = 3.1 DEGREES REMARK 500 ARG A 150 NE - CZ - NH2 ANGL. DEV. = -5.4 DEGREES REMARK 500 ARG C 150 NE - CZ - NH1 ANGL. DEV. = 3.8 DEGREES REMARK 500 ARG C 150 NE - CZ - NH2 ANGL. DEV. = -5.1 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLU A 8 143.16 -174.50 REMARK 500 GLU A 40 0.56 97.79 REMARK 500 THR A 41 -124.83 -166.98 REMARK 500 LEU A 58 65.32 -113.28 REMARK 500 ASP A 127 41.09 -150.17 REMARK 500 ASP A 145 78.89 53.98 REMARK 500 GLU A 162 66.48 -66.26 REMARK 500 VAL A 164 131.74 76.85 REMARK 500 SER A 181 -142.89 -144.34 REMARK 500 ARG A 199 -2.23 76.28 REMARK 500 TRP A 227 89.75 -152.19 REMARK 500 HIS A 295 35.89 -79.84 REMARK 500 PRO B 176 -159.66 -98.06 REMARK 500 PHE B 304 15.79 58.86 REMARK 500 TRP B 372 115.12 -29.79 REMARK 500 GLU C 8 145.70 -176.43 REMARK 500 THR C 39 -2.48 56.94 REMARK 500 GLU C 40 -78.86 -142.74 REMARK 500 THR C 41 -66.42 -91.71 REMARK 500 LEU C 58 64.91 -117.87 REMARK 500 ASP C 127 48.64 -152.60 REMARK 500 ASP C 145 75.33 57.61 REMARK 500 VAL C 164 131.30 72.87 REMARK 500 SER C 181 -142.81 -136.19 REMARK 500 ARG C 199 -25.82 95.14 REMARK 500 PRO C 254 -7.60 -59.40 REMARK 500 LYS C 291 78.66 -118.67 REMARK 500 LEU C 296 178.12 79.79 REMARK 500 PRO D 176 -160.61 -66.54 REMARK 500 TRP D 372 109.67 -33.39 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 ASP A 38 THR A 39 126.78 REMARK 500 GLU C 40 THR C 41 -149.18 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE C95 A1297 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE C95 C1297 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE REMARK 900 INHIBITOR INDIRUBIN-5- SULPHONATE BOUND REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU2058 REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6094 REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6086 REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6102 REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P53 REMARK 900 RELATED ID: 1H27 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P27 REMARK 900 RELATED ID: 1H28 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P107 REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1OGU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2- REMARK 900 ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1OI9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OIU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OIY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OKV RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2 REMARK 900 RELATED ID: 1OKW RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2 REMARK 900 RELATED ID: 1OL1 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1OL2 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1P5E RELATED DB: PDB REMARK 900 THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR REMARK 900 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS) REMARK 900 RELATED ID: 1PKD RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN REMARK 900 A REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX REMARK 900 RELATED ID: 1URC RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1VYW RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 REMARK 900 RELATED ID: 2BKZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 REMARK 900 RELATED ID: 2BPM RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 REMARK 900 RELATED ID: 2C4G RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 REMARK 900 RELATED ID: 2C5N RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5O RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5P RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5T RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5V RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5X RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C6T RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2CCH RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE REMARK 900 PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE REMARK 900 RELATED ID: 2CCI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A REMARK 900 PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6 REMARK 900 RELATED ID: 2CJM RELATED DB: PDB REMARK 900 MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 REMARK 900 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE REMARK 900 RELATED ID: 2IW6 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A COMPLEXED WITH A REMARK 900 BISANILINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2IW8 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A F82H-L83V-H84D REMARK 900 MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR REMARK 900 RELATED ID: 2IW9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A COMPLEXED WITH A REMARK 900 BISANILINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2UUE RELATED DB: PDB REMARK 900 REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE REMARK 900 INHIBITORS REMARK 900 RELATED ID: 2UZB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2UZD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2UZL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2UZN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2UZO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 999 REMARK 999 SEQUENCE REMARK 999 RESIDUES 175 - 432 CYCLIN A2 DBREF 2UZE A 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 2UZE B 175 432 UNP P20248 CCNA2_HUMAN 175 432 DBREF 2UZE C 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 2UZE D 175 432 UNP P20248 CCNA2_HUMAN 175 432 SEQRES 1 A 298 MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU GLY SEQRES 2 A 298 THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU THR SEQRES 3 A 298 GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP THR SEQRES 4 A 298 GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU ILE SEQRES 5 A 298 SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL LYS SEQRES 6 A 298 LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR LEU SEQRES 7 A 298 VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE MET SEQRES 8 A 298 ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU ILE SEQRES 9 A 298 LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA PHE SEQRES 10 A 298 CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS PRO SEQRES 11 A 298 GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS LEU SEQRES 12 A 298 ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO VAL SEQRES 13 A 298 ARG THR TYR TPO HIS GLU VAL VAL THR LEU TRP TYR ARG SEQRES 14 A 298 ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER THR SEQRES 15 A 298 ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA GLU SEQRES 16 A 298 MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER GLU SEQRES 17 A 298 ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY THR SEQRES 18 A 298 PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET PRO SEQRES 19 A 298 ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN ASP SEQRES 20 A 298 PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY ARG SEQRES 21 A 298 SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN LYS SEQRES 22 A 298 ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE PHE SEQRES 23 A 298 GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU SEQRES 1 B 258 VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR LEU ARG SEQRES 2 B 258 GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY TYR MET SEQRES 3 B 258 LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG ALA ILE SEQRES 4 B 258 LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU TYR LYS SEQRES 5 B 258 LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN TYR ILE SEQRES 6 B 258 ASP ARG PHE LEU SER SER MET SER VAL LEU ARG GLY LYS SEQRES 7 B 258 LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU ALA SER SEQRES 8 B 258 LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA GLU PHE SEQRES 9 B 258 VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS GLN VAL SEQRES 10 B 258 LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU THR PHE SEQRES 11 B 258 ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU THR GLN SEQRES 12 B 258 TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS VAL GLU SEQRES 13 B 258 SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU ILE ASP SEQRES 14 B 258 ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL ILE ALA SEQRES 15 B 258 GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL THR GLY SEQRES 16 B 258 GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR GLY TYR SEQRES 17 B 258 THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP LEU HIS SEQRES 18 B 258 GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN GLN SER SEQRES 19 B 258 ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS GLY VAL SEQRES 20 B 258 SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU SEQRES 1 C 298 MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU GLY SEQRES 2 C 298 THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU THR SEQRES 3 C 298 GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP THR SEQRES 4 C 298 GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU ILE SEQRES 5 C 298 SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL LYS SEQRES 6 C 298 LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR LEU SEQRES 7 C 298 VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE MET SEQRES 8 C 298 ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU ILE SEQRES 9 C 298 LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA PHE SEQRES 10 C 298 CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS PRO SEQRES 11 C 298 GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS LEU SEQRES 12 C 298 ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO VAL SEQRES 13 C 298 ARG THR TYR TPO HIS GLU VAL VAL THR LEU TRP TYR ARG SEQRES 14 C 298 ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER THR SEQRES 15 C 298 ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA GLU SEQRES 16 C 298 MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER GLU SEQRES 17 C 298 ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY THR SEQRES 18 C 298 PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET PRO SEQRES 19 C 298 ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN ASP SEQRES 20 C 298 PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY ARG SEQRES 21 C 298 SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN LYS SEQRES 22 C 298 ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE PHE SEQRES 23 C 298 GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU SEQRES 1 D 258 VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR LEU ARG SEQRES 2 D 258 GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY TYR MET SEQRES 3 D 258 LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG ALA ILE SEQRES 4 D 258 LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU TYR LYS SEQRES 5 D 258 LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN TYR ILE SEQRES 6 D 258 ASP ARG PHE LEU SER SER MET SER VAL LEU ARG GLY LYS SEQRES 7 D 258 LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU ALA SER SEQRES 8 D 258 LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA GLU PHE SEQRES 9 D 258 VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS GLN VAL SEQRES 10 D 258 LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU THR PHE SEQRES 11 D 258 ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU THR GLN SEQRES 12 D 258 TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS VAL GLU SEQRES 13 D 258 SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU ILE ASP SEQRES 14 D 258 ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL ILE ALA SEQRES 15 D 258 GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL THR GLY SEQRES 16 D 258 GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR GLY TYR SEQRES 17 D 258 THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP LEU HIS SEQRES 18 D 258 GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN GLN SER SEQRES 19 D 258 ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS GLY VAL SEQRES 20 D 258 SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU MODRES 2UZE TPO A 160 THR PHOSPHOTHREONINE MODRES 2UZE TPO C 160 THR PHOSPHOTHREONINE HET TPO A 160 11 HET TPO C 160 11 HET C95 A1297 22 HET C95 C1297 22 HETNAM TPO PHOSPHOTHREONINE HETNAM C95 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE) HETNAM 2 C95 METHYL]FURAN-2-YL}BENZOIC ACID HETSYN TPO PHOSPHONOTHREONINE FORMUL 1 TPO 2(C4 H10 N O6 P) FORMUL 5 C95 2(C15 H10 N2 O4 S) FORMUL 7 HOH *296(H2 O) HELIX 1 1 PRO A 45 LEU A 58 1 14 HELIX 2 2 LEU A 87 SER A 94 1 8 HELIX 3 3 PRO A 100 HIS A 121 1 22 HELIX 4 4 THR A 165 ARG A 169 5 5 HELIX 5 5 ALA A 170 LEU A 175 1 6 HELIX 6 6 THR A 182 ARG A 199 1 18 HELIX 7 7 SER A 207 GLY A 220 1 14 HELIX 8 8 GLY A 229 MET A 233 5 5 HELIX 9 9 ASP A 247 VAL A 252 1 6 HELIX 10 10 ASP A 256 LEU A 267 1 12 HELIX 11 11 SER A 276 ALA A 282 1 7 HELIX 12 12 HIS A 283 GLN A 287 5 5 HELIX 13 13 TYR B 178 CYS B 193 1 16 HELIX 14 14 GLY B 198 GLN B 203 5 6 HELIX 15 15 THR B 207 LYS B 226 1 20 HELIX 16 16 GLN B 228 MET B 246 1 19 HELIX 17 17 LEU B 249 GLY B 251 5 3 HELIX 18 18 LYS B 252 GLU B 269 1 18 HELIX 19 19 GLU B 274 THR B 282 1 9 HELIX 20 20 THR B 287 LEU B 302 1 16 HELIX 21 21 THR B 310 LEU B 320 1 11 HELIX 22 22 ASN B 326 ASP B 343 1 18 HELIX 23 23 ASP B 343 LEU B 348 1 6 HELIX 24 24 LEU B 351 GLY B 369 1 19 HELIX 25 25 PRO B 373 GLY B 381 1 9 HELIX 26 26 LEU B 387 ALA B 401 1 15 HELIX 27 27 PRO B 402 HIS B 404 5 3 HELIX 28 28 GLN B 407 TYR B 413 1 7 HELIX 29 29 LYS B 414 HIS B 419 5 6 HELIX 30 30 PRO C 45 GLU C 57 1 13 HELIX 31 31 LEU C 87 SER C 94 1 8 HELIX 32 32 PRO C 100 SER C 120 1 21 HELIX 33 33 LYS C 129 GLN C 131 5 3 HELIX 34 34 ASP C 145 ALA C 149 5 5 HELIX 35 35 THR C 165 ARG C 169 5 5 HELIX 36 36 ALA C 170 LEU C 175 1 6 HELIX 37 37 THR C 182 ARG C 199 1 18 HELIX 38 38 SER C 207 GLY C 220 1 14 HELIX 39 39 GLY C 229 MET C 233 5 5 HELIX 40 40 ASP C 247 VAL C 252 1 6 HELIX 41 41 ASP C 256 LEU C 267 1 12 HELIX 42 42 SER C 276 LEU C 281 1 6 HELIX 43 43 HIS C 283 GLN C 287 5 5 HELIX 44 44 TYR D 178 CYS D 193 1 16 HELIX 45 45 THR D 207 TYR D 225 1 19 HELIX 46 46 GLN D 228 MET D 246 1 19 HELIX 47 47 LEU D 249 GLY D 251 5 3 HELIX 48 48 LYS D 252 GLU D 269 1 18 HELIX 49 49 GLU D 274 THR D 282 1 9 HELIX 50 50 THR D 287 LEU D 302 1 16 HELIX 51 51 THR D 310 LEU D 320 1 11 HELIX 52 52 ASN D 326 ASP D 343 1 18 HELIX 53 53 ASP D 343 LEU D 348 1 6 HELIX 54 54 LEU D 351 GLY D 369 1 19 HELIX 55 55 PRO D 373 GLY D 381 1 9 HELIX 56 56 THR D 383 ALA D 401 1 19 HELIX 57 57 PRO D 402 HIS D 404 5 3 HELIX 58 58 GLN D 407 TYR D 413 1 7 HELIX 59 59 LYS D 414 HIS D 419 5 6 HELIX 60 60 GLY D 420 LEU D 424 5 5 SHEET 1 AA 5 PHE A 4 GLU A 12 0 SHEET 2 AA 5 VAL A 17 ASN A 23 -1 O VAL A 18 N ILE A 10 SHEET 3 AA 5 VAL A 29 ARG A 36 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LYS A 75 GLU A 81 -1 O LEU A 76 N ILE A 35 SHEET 5 AA 5 LEU A 66 HIS A 71 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 SHEET 1 AC 2 VAL A 123 LEU A 124 0 SHEET 2 AC 2 ARG A 150 ALA A 151 -1 O ARG A 150 N LEU A 124 SHEET 1 CA 5 PHE C 4 GLU C 12 0 SHEET 2 CA 5 VAL C 17 ASN C 23 -1 O VAL C 18 N ILE C 10 SHEET 3 CA 5 VAL C 29 ARG C 36 -1 O VAL C 30 N ALA C 21 SHEET 4 CA 5 LYS C 75 GLU C 81 -1 O LEU C 76 N ILE C 35 SHEET 5 CA 5 LEU C 66 HIS C 71 -1 N LEU C 67 O VAL C 79 SHEET 1 CB 3 GLN C 85 ASP C 86 0 SHEET 2 CB 3 LEU C 133 ILE C 135 -1 O ILE C 135 N GLN C 85 SHEET 3 CB 3 ILE C 141 LEU C 143 -1 O LYS C 142 N LEU C 134 SHEET 1 CC 2 VAL C 123 LEU C 124 0 SHEET 2 CC 2 ARG C 150 ALA C 151 -1 O ARG C 150 N LEU C 124 LINK C TYR A 159 N TPO A 160 1555 1555 1.33 LINK C TPO A 160 N HIS A 161 1555 1555 1.33 LINK C TYR C 159 N TPO C 160 1555 1555 1.33 LINK C TPO C 160 N HIS C 161 1555 1555 1.33 CISPEP 1 VAL A 154 PRO A 155 0 -4.30 CISPEP 2 GLN B 323 PRO B 324 0 -12.62 CISPEP 3 ASP B 345 PRO B 346 0 10.50 CISPEP 4 VAL C 154 PRO C 155 0 -12.66 CISPEP 5 GLN D 323 PRO D 324 0 -9.42 CISPEP 6 ASP D 345 PRO D 346 0 9.62 SITE 1 AC1 14 ILE A 10 GLY A 13 ALA A 31 LYS A 33 SITE 2 AC1 14 GLU A 51 PHE A 80 GLU A 81 LEU A 83 SITE 3 AC1 14 HIS A 84 GLN A 85 ASP A 86 LYS A 89 SITE 4 AC1 14 LEU A 134 ASP A 145 SITE 1 AC2 13 ILE C 10 GLY C 13 ALA C 31 LYS C 33 SITE 2 AC2 13 PHE C 80 GLU C 81 LEU C 83 HIS C 84 SITE 3 AC2 13 ASP C 86 LYS C 89 LEU C 134 ASP C 145 SITE 4 AC2 13 HOH C2010 CRYST1 212.626 73.436 153.028 90.00 129.54 90.00 C 1 2 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.004703 0.000000 0.003882 0.00000 SCALE2 0.000000 0.013617 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008474 0.00000